Abbott Laboratories (ABT) to Host Conference Call on January 22, 2026, for Q4 2025 Earnings Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
Source: NASDAQ.COM
- Earnings Call Announcement: Abbott Laboratories is set to host a conference call on January 22, 2026, at 9:00 AM ET to discuss its Q4 2025 earnings results, aiming to provide investors with the latest financial insights and company developments.
- Live Webcast Access: Investors can access the live webcast of the call through Abbott's investor website, ensuring transparency and enhancing communication with shareholders, reflecting the company's commitment to investor relations.
- Enhanced Financial Transparency: By conducting regular earnings calls, Abbott not only communicates performance information to the market in a timely manner but also boosts investor confidence in the company's future prospects, potentially leading to positive stock price impacts.
- Strategic Communication Platform: This call will serve as a strategic communication platform for Abbott to share the latest advancements and future outlook in the healthcare sector, further solidifying its leadership position in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 94.120
Low
136.00
Averages
148.11
High
169.00
Current: 94.120
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Defensive Dividend Stock Investment Opportunities Amid Market Concerns
- AbbVie's Growth Potential: After losing the patent for Humira in 2023, AbbVie expects to generate over $31 billion in sales by 2027 from newer drugs like Skyrizi and Rinvoq, demonstrating strong growth potential in the biopharmaceutical sector, while its dividend payout ratio remains at a low 59%, providing stable returns for investors.
- Johnson & Johnson's Strength: Johnson & Johnson has raised its dividend for 64 consecutive years, currently offering a 2.1% yield, with its Innovative Medicine segment driving future growth; analysts project adjusted EPS to rise by 7% and 10% in 2026 and 2027, respectively, showcasing resilience amid market fluctuations.
- Pfizer's Risks and Opportunities: Pfizer's stock soared during the pandemic due to COVID-19 vaccine sales but has since declined; despite facing patent cliffs and competitive pressures, it has secured patent extensions for Vyndamax, which may support future growth and recovery.
- Market Environment and Investment Strategy: With the S&P 500 trading at historically high P/E ratios, investors are advised to consider defensive dividend stocks, which may decline during market downturns but offer steady income and potential capital appreciation for patient investors.
See More
U.S. Justice Department Closes Criminal Probe into Abbott Laboratories
- Investigation Closure: The U.S. Justice Department has decided to close its criminal probe into Abbott Laboratories, opting for civil penalties instead, which may alleviate some negative impacts on the company's reputation regarding its handling of a baby formula plant.
- Mild Penalties: Although prosecutors considered criminal charges against Abbott, they ultimately chose to recover profits earned from selling formula through federally funded nutrition programs, indicating a softer regulatory approach from the government.
- Recall Impact: Abbott initiated a recall and closed its Michigan plant in 2022 after traces of potentially deadly bacteria were found, exacerbating a national baby formula shortage that had already begun due to pandemic-related supply chain issues.
- Safety Priority: A DOJ spokesperson emphasized that ensuring the safety of the nation's food supply is a top priority, and while no criminal charges were pursued against Abbott, this reflects a significant focus on food safety regulation that may influence future industry oversight.
See More
Abbott Laboratories: A Safe Harbor Stock Choice
- Dividend Growth Potential: Abbott Laboratories has raised its quarterly cash dividend for 55 consecutive years, currently offering a yield of approximately 2.8%; despite a slowdown in growth, its payout ratio of 41.6% suggests sustainable long-term dividend increases, providing investors with stable returns.
- Acquisition Impact Analysis: Abbott's $21 billion acquisition of Exact Sciences is expected to dilute earnings in the short term, but in the long run, this deal positions Abbott as a leader in cancer diagnostics, likely driving future earnings and dividend growth.
- Market Valuation Advantage: Trading at a price-to-earnings ratio of 16.5, Abbott is more attractively valued compared to competitors like Johnson & Johnson, which trades above 20 times earnings, presenting a potentially better buying opportunity for investors.
- Defensive Investment Characteristics: As a blue-chip Dividend King, Abbott offers a relatively safe investment choice amid increasing market volatility, with its stable dividends and potential for capital appreciation making it an ideal candidate for long-term portfolios, especially in uncertain economic conditions.
See More
Abbott Laboratories: A Preferred Defensive Investment
- Dividend King Status: Abbott Laboratories has raised its quarterly cash dividend for 55 consecutive years, currently offering a yield of approximately 2.8%, and while growth has slowed, the consistent dividend increases provide reliable returns for investors over the long term.
- Acquisition-Driven Growth: Abbott's $21 billion acquisition of Exact Sciences is expected to dilute earnings in the short term, yet this strategic move positions the company as a leader in cancer diagnostics, laying the groundwork for future growth.
- Relative Valuation Advantage: Trading at a forward P/E of 16.5 times, Abbott is valued lower than competitors like Johnson & Johnson, which trades over 20 times, highlighting its attractiveness among diversified healthcare stocks, especially during market volatility.
- Market Safe Haven: As market uncertainty rises, investors typically gravitate towards defensive dividend stocks, and Abbott, with its solid financial performance and growth potential, could serve as a safe harbor for investors, particularly in times of economic fluctuations.
See More
Investors Seek High Dividend Stocks Amid Market Volatility
- Market Valuation: Despite increased market volatility, veteran investor Jeremy Grantham highlights that we are in the most expensive market in U.S. history, prompting investors to seek high dividend stocks for income while waiting for asset appreciation, thereby providing a stable cash flow in an uncertain economic environment.
- Dividend Stock Screening: CNBC Pro screened the Vanguard Dividend Appreciation Index Fund ETF and found stocks with dividend yields above 1.5%, where over 55% of analysts rated them as buys, and price targets are at least 20% above current trading prices, indicating strong market confidence in these stocks.
- Abbott Laboratories Performance: Abbott Laboratories offers a 2.7% dividend yield and has fallen nearly 10% in the past three months, yet analysts see a 23% upside potential, with 79% rating it a buy, reflecting its long-term growth potential in the healthcare sector.
- Medtronic's Growth Potential: Medtronic yields 3.6% and has dropped 8% in the last three months, but analysts believe it has a 19% upside potential, and the company's investments in emerging medical technologies are expected to drive future growth, with 64% of analysts rating it a buy.
See More
Abbott to Announce Q2 2026 Financial Results on July 16
- Earnings Announcement Schedule: Abbott is set to release its Q2 2026 financial results on July 16 before market open, reflecting the company's commitment to transparency and investor communication aimed at bolstering market confidence.
- Live Webcast Conference: Following the earnings release, Abbott will host a live webcast of the earnings conference call at 8 a.m. Central Time (9 a.m. Eastern), facilitating timely information access for global investors and enhancing company-investor interaction.
- Investor Relations Website: Investors can access the earnings report and archived conference call through Abbott's Investor Relations website, further improving information accessibility and demonstrating the company's commitment to investor service.
- Global Business Overview: Abbott operates in over 160 countries with 122,000 employees, covering diagnostics, medical devices, nutritionals, and branded generic medicines, showcasing its leadership position in the healthcare industry.
See More
Defensive Dividend Stock Investment Opportunities Amid Market Concerns
- AbbVie's Growth Potential: After losing the patent for Humira in 2023, AbbVie expects to generate over $31 billion in sales by 2027 from newer drugs like Skyrizi and Rinvoq, demonstrating strong growth potential in the biopharmaceutical sector, while its dividend payout ratio remains at a low 59%, providing stable returns for investors.
- Johnson & Johnson's Strength: Johnson & Johnson has raised its dividend for 64 consecutive years, currently offering a 2.1% yield, with its Innovative Medicine segment driving future growth; analysts project adjusted EPS to rise by 7% and 10% in 2026 and 2027, respectively, showcasing resilience amid market fluctuations.
- Pfizer's Risks and Opportunities: Pfizer's stock soared during the pandemic due to COVID-19 vaccine sales but has since declined; despite facing patent cliffs and competitive pressures, it has secured patent extensions for Vyndamax, which may support future growth and recovery.
- Market Environment and Investment Strategy: With the S&P 500 trading at historically high P/E ratios, investors are advised to consider defensive dividend stocks, which may decline during market downturns but offer steady income and potential capital appreciation for patient investors.
See More
U.S. Justice Department Closes Criminal Probe into Abbott Laboratories
- Investigation Closure: The U.S. Justice Department has decided to close its criminal probe into Abbott Laboratories, opting for civil penalties instead, which may alleviate some negative impacts on the company's reputation regarding its handling of a baby formula plant.
- Mild Penalties: Although prosecutors considered criminal charges against Abbott, they ultimately chose to recover profits earned from selling formula through federally funded nutrition programs, indicating a softer regulatory approach from the government.
- Recall Impact: Abbott initiated a recall and closed its Michigan plant in 2022 after traces of potentially deadly bacteria were found, exacerbating a national baby formula shortage that had already begun due to pandemic-related supply chain issues.
- Safety Priority: A DOJ spokesperson emphasized that ensuring the safety of the nation's food supply is a top priority, and while no criminal charges were pursued against Abbott, this reflects a significant focus on food safety regulation that may influence future industry oversight.
See More
Abbott Laboratories: A Safe Harbor Stock Choice
- Dividend Growth Potential: Abbott Laboratories has raised its quarterly cash dividend for 55 consecutive years, currently offering a yield of approximately 2.8%; despite a slowdown in growth, its payout ratio of 41.6% suggests sustainable long-term dividend increases, providing investors with stable returns.
- Acquisition Impact Analysis: Abbott's $21 billion acquisition of Exact Sciences is expected to dilute earnings in the short term, but in the long run, this deal positions Abbott as a leader in cancer diagnostics, likely driving future earnings and dividend growth.
- Market Valuation Advantage: Trading at a price-to-earnings ratio of 16.5, Abbott is more attractively valued compared to competitors like Johnson & Johnson, which trades above 20 times earnings, presenting a potentially better buying opportunity for investors.
- Defensive Investment Characteristics: As a blue-chip Dividend King, Abbott offers a relatively safe investment choice amid increasing market volatility, with its stable dividends and potential for capital appreciation making it an ideal candidate for long-term portfolios, especially in uncertain economic conditions.
See More
Abbott Laboratories: A Preferred Defensive Investment
- Dividend King Status: Abbott Laboratories has raised its quarterly cash dividend for 55 consecutive years, currently offering a yield of approximately 2.8%, and while growth has slowed, the consistent dividend increases provide reliable returns for investors over the long term.
- Acquisition-Driven Growth: Abbott's $21 billion acquisition of Exact Sciences is expected to dilute earnings in the short term, yet this strategic move positions the company as a leader in cancer diagnostics, laying the groundwork for future growth.
- Relative Valuation Advantage: Trading at a forward P/E of 16.5 times, Abbott is valued lower than competitors like Johnson & Johnson, which trades over 20 times, highlighting its attractiveness among diversified healthcare stocks, especially during market volatility.
- Market Safe Haven: As market uncertainty rises, investors typically gravitate towards defensive dividend stocks, and Abbott, with its solid financial performance and growth potential, could serve as a safe harbor for investors, particularly in times of economic fluctuations.
See More
Investors Seek High Dividend Stocks Amid Market Volatility
- Market Valuation: Despite increased market volatility, veteran investor Jeremy Grantham highlights that we are in the most expensive market in U.S. history, prompting investors to seek high dividend stocks for income while waiting for asset appreciation, thereby providing a stable cash flow in an uncertain economic environment.
- Dividend Stock Screening: CNBC Pro screened the Vanguard Dividend Appreciation Index Fund ETF and found stocks with dividend yields above 1.5%, where over 55% of analysts rated them as buys, and price targets are at least 20% above current trading prices, indicating strong market confidence in these stocks.
- Abbott Laboratories Performance: Abbott Laboratories offers a 2.7% dividend yield and has fallen nearly 10% in the past three months, yet analysts see a 23% upside potential, with 79% rating it a buy, reflecting its long-term growth potential in the healthcare sector.
- Medtronic's Growth Potential: Medtronic yields 3.6% and has dropped 8% in the last three months, but analysts believe it has a 19% upside potential, and the company's investments in emerging medical technologies are expected to drive future growth, with 64% of analysts rating it a buy.
See More
Abbott to Announce Q2 2026 Financial Results on July 16
- Earnings Announcement Schedule: Abbott is set to release its Q2 2026 financial results on July 16 before market open, reflecting the company's commitment to transparency and investor communication aimed at bolstering market confidence.
- Live Webcast Conference: Following the earnings release, Abbott will host a live webcast of the earnings conference call at 8 a.m. Central Time (9 a.m. Eastern), facilitating timely information access for global investors and enhancing company-investor interaction.
- Investor Relations Website: Investors can access the earnings report and archived conference call through Abbott's Investor Relations website, further improving information accessibility and demonstrating the company's commitment to investor service.
- Global Business Overview: Abbott operates in over 160 countries with 122,000 employees, covering diagnostics, medical devices, nutritionals, and branded generic medicines, showcasing its leadership position in the healthcare industry.
See More
